2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Molecular Testing, Bioinformatics, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Computer Vision, Deep Learning, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Diseases, Infectious Diseases, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Fundamental Science, AML, APL, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

5108 NUP98 rearrangements in acute myeloid leukemia: Fusion partner-specific prognosis and role of allogeneic transplantation

Yang Miao, Hongming Zhu2, Qinrong Wang3, Yan Hui4, Wen-Yan Cheng5, Man Qiao, MD6, Man Wang7, Jundan Xie8, Hongjie Shen9, Yingchang Mi, MD10, Jianxiang Wang Sr, MD, PhD11, Suning Chen12, Yang Shen, PhD13, Hui Wei, MD, PhD14
1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, shanghai, China
3 The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, suzhou, China
4 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, shanghai, China
6 Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, suzhou, China
7 Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, suzhou, China
8 Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, suzhou, China
9 Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, suzhou, China
10 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
11 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
12 Department of Hematology, The First Affiliated Hospital of Soochow University, National Clinical Research Center for Hematologic Diseases, suzhou, China
13 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, shanghai, China
14 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

NUP98 rearrangements (NUP98-r) define a rare, aggressive subtype of acute myeloid leukemia (AML) recognized by the 2022 World Health Organization (WHO) and International Consensus Classification (ICC) but lacking specific risk stratification in the 2022 European LeukemiaNet (ELN) recommendations. To unbiasedly assess their prognostic impact, we performed comprehensive whole transcriptome RNA sequencing in a large consecutive multicenter cohort comprising 2,829 adult non-acute promyelocytic leukemia (non-APL) AML patients diagnosed between January 2019 and June 2025.
After exclusion of untreated cases and those without RNA sequencing data, 108 NUP98-r patients (3.8%) were identified. Eighteen distinct fusion partners were detected. The most frequent fusion was NUP98::NSD1 (56.5%), followed by NUP98::HOXA9 (15.7%), along with two novel fusions (NUP98::CDCA7L, and NUP98::EEF1A1). NUP98-r patients were younger (median age 43 vs. 47 years, P=0.015) and had higher white blood cell counts (median 35.6 vs. 12.5 ×10?/L, P<0.001). Their overall survival (OS) approximated that of the adverse-risk group, yet marked heterogeneity existed across fusion partners. NUP98::HOXA9 conferred favorable survival approaching the favorable-risk group (2-year OS 88.9%), whereas NUP98::NSD1 and other fusions were associated with poor outcomes resembling adverse-risk disease. Notably, allogeneic hematopoietic stem cell transplantation in first remission consistently improved survival in NUP98-r patients, with the benefit particularly pronounced in the NUP98::NSD1 subgroup (2-year OS: 91.3% with transplantation vs. 48.2% without).
As one of the largest cohorts to date, this study establishes NUP98-r as a prognostically relevant entity with marked fusion-partner heterogeneity and supports early transplantation, especially for NUP98::NSD1 patients.

Yang Miao: No relevant conflicts of interest to declare.